A Phase 1 interventional study of AZD6793 and Placebo in Inflammatory Diseases, sponsored by AstraZeneca. Completed at 2 sites in United Kingdom. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-29.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the study is to assess the safety and tolerability of AZD6793 suspension following oral administration of Single Ascending Dose (SAD) [Part 1] and Multiple Ascending Dose (MAD) [Part 2] in healthy participants.
Additionally, the study will include Part 3 (bioavailability and food effect cohort) to assess the relative oral bioavailability between test formulation and oral suspension (reference formulation) as well as the effect of a high fat high calorie (HFHC) meal on the PK of AZD6793 test formulation, in comparison to fasting conditions, after a single oral dose of AZD6793 in healthy participants.
Part 4 of the study (Chronic Obstructive Pulmonary Disease [COPD] cohort) is intended to evaluate AZD6793 safety, tolerability, and PK profile for the first time in participants with moderate to severe COPD.
Part 1 (SAD), Part 2 (MAD) and Part 3 (Bioavailability and food effect cohort) have been completed. Although it was planned that 5 cohorts would be included in Part 1, only 4 cohorts (32 participants) were included. Part 3 of the study was concluded with 13 healthy participants.
Parts 1, 2, and 3 were conducted in a single center and Part 4 is conducted in 2 centers.
Part 1 of the study will comprise:
Part 2 of the study will comprise:
Part 3 of the study will comprise:
Part 4 of the study will comprise:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Main Inclusion Criteria:
Parts 1,2 and 3:
Part 4:
Females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit, must not be lactating and must be of :
Main Exclusion Criteria:
Parts 1,2 and 3:
Part 4:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
6 Healthy participants will receive a single oral dose A of AZD6793 and 2 healthy participants will receive placebo
Drug: AZD6793 · Drug: Placebo
6 Healthy participants will receive a single oral dose B of AZD6793 and 2 healthy participants will receive placebo
Drug: AZD6793 · Drug: Placebo
6 Healthy participants will receive a single oral dose C of AZD6793 and 2 healthy participants will receive placebo
Drug: AZD6793 · Drug: Placebo
6 Healthy participants will receive a single oral dose D of AZD6793 and 2 healthy participants will receive placebo
Drug: AZD6793 · Drug: Placebo
6 Healthy participants will receive a single oral dose E of AZD6793 and 2 healthy participants will receive placebo
Drug: AZD6793 · Drug: Placebo
6 Healthy participants will receive dose W of AZD6793 and 2 healthy participants will receive placebo once daily on Day 1 and 8 and twice daily on Day 3 to Day 7
Drug: AZD6793 · Drug: Placebo
6 Healthy participants will receive dose X of AZD6793 and 2 healthy participants will receive placebo once daily on Day 1 and 8 and twice daily on Day 3 to Day 7
Drug: AZD6793 · Drug: Placebo
6 Healthy participants will receive dose Y of AZD6793 and 2 healthy participants will receive placebo once daily on Day 1 and 8 and twice daily on Day 3 to Day 7
Drug: AZD6793 · Drug: Placebo
6 Healthy participants will receive dose Z of AZD6793 and 2 healthy participants will receive placebo once daily on Day 1 and 8 and twice daily on Day 3 to Day 7
Drug: AZD6793 · Drug: Placebo
Participants will receive a single oral dose of test formulation AZD6793 in fasted state, test formulation AZD6793 in fed state following reference formulation AZD6793 in fasted state once on Day 1 of each treatment period.
Drug: AZD6793
Participants will receive a single oral dose of test formulation AZD6793 in fed state, reference formulation AZD6793 in fasted state following test formulation AZD6793 in fasted state once on Day 1 of each treatment period.
Drug: AZD6793
Participants will receive a single oral dose of reference formulation AZD6793 in fasted state, test formulation AZD6793 in fasted state following test formulation AZD6793 in fed state once on Day 1 of each treatment period.
Drug: AZD6793
10 participants with COPD will receive AZD6793 once daily and 5 participants with COPD will receive placebo
Drug: AZD6793 · Drug: Placebo
AZD6793 will be administered orally
Placebo will be administered orally
Part 1 (SAD): Number of participants with adverse events
Safety and tolerability of AZD6793 following oral administration of SAD in healthy participants.
Time frame: From screening up to Follow up visit (Day 6±1)
Part 2 (MAD): Number of participants with adverse events
Safety and tolerability of AZD6793 following oral administration of MAD in healthy participants.
Time frame: From screening up to Follow up visit (Day 14±1)
Part 1 (SAD): Number of participants with abnormal findings in vital signs (supine Blood Pressure (BP), pulse, respiratory rate, peripheral oxygen saturation (SpO2) and oral body temperature)
Safety and tolerability of AZD6793 following oral administration of SAD in healthy participants.
Time frame: From screening, Treatment Day 1 to Day 4 up to Follow up visit (Day 6±1)
Part 2 (MAD): Number of participants with abnormal findings in vital signs (supine Blood Pressure (BP), pulse, respiratory rate, peripheral oxygen saturation (SpO2) and oral body temperature)
Safety and tolerability of AZD6793 following oral administration of MAD in healthy participants.
Time frame: From screening, Treatment Day -1 to Day 10 up to Follow up visit (Day 14±1)
Part 1 (SAD): Number of participants with abnormal findings in 12 Lead electrocardiogram (ECG)
Safety and tolerability of AZD6793 following oral administration of SAD in healthy participants.
Time frame: From screening, Treatment Day -1 to Day 4 up to Follow up visit (Day 6±1)
Part 2 (MAD): Number of participants with abnormal findings in 12 Lead electrocardiogram (ECG)
Safety and tolerability of AZD6793 following oral administration of MAD in healthy participants.
Time frame: From screening, Treatment Day -1 to Day 10 up to Follow up visit (Day 14±1)
Part 1 (SAD): Number of participants with abnormal findings in 12 Lead Digital electrocardiogram (dECG)
Safety and tolerability of AZD6793 following oral administration of SAD in healthy participants.
Time frame: Day 1 to Day 3
Part 2 (MAD): Number of participants with abnormal findings in 12 Lead Digital electrocardiogram (dECG)
Safety and tolerability of AZD6793 following oral administration of MAD in healthy participants.
Time frame: Day 1 to Day 3, Day 5, Day 8 to Day 10
Part 1 (SAD): Number of participants with abnormal findings in Telemetry
Safety and tolerability of AZD6793 following oral administration of SAD in healthy participants.
Time frame: Day -1 to Day 3
Part 2 (MAD): Number of participants with abnormal findings in Telemetry
Safety and tolerability of AZD6793 following oral administration of MAD in healthy participants.
Time frame: Day -1 to Day 2 and Day 8 to Day 10
Part 1 (SAD): Number of participants with abnormal findings in Physical examinations
Safety and tolerability of AZD6793 following oral administration of SAD in healthy participants.
Time frame: From screening, Treatment Day -1 to 4 and follow up visit
Part 2 (MAD): Number of participants with abnormal findings in Physical examinations
Safety and tolerability of AZD6793 following oral administration of MAD in healthy participants.
Time frame: From screening, Treatment Day -1 to 10 and follow up visit
Part 1 (SAD): Number of participants with abnormal findings in Laboratory assessments (haematology, serum clinical chemistry, and urinalysis)
Safety and tolerability of AZD6793 following oral administration of SAD in healthy participants.
Time frame: From screening, Treatment Day -1, Day 2, Day 4 and Follow up visit (Day 6±1)
Part 2 (MAD): Number of participants with abnormal findings in Laboratory assessments (haematology, serum clinical chemistry, and urinalysis)
Safety and tolerability of AZD6793 following oral administration of MAD in healthy participants.
Time frame: From screening, Treatment Day -1 to Day 10 up to Follow up visit (Day 14±1)
Part 3 (Bioavailability): Maximum observed plasma (peak) drug concentration [Cmax]
Evaluating the relative oral bioavailability between the test formulation and the reference formulation after a single oral dose of AZD6793 in healthy participants.
Time frame: Day 1 to Day 3
Part 3 (Bioavailability): Area under plasma concentration-time curve from zero to infinity [AUCinf]
Evaluating the relative oral bioavailability between the test formulation and the reference formulation after a single oral dose of AZD6793 in healthy participants.
Time frame: Day 1 to Day 3
Part 3 (Food effect): Cmax of AZD6793
Investigating the effect of a high fat high calorie (HFHC) meal compared to fasting conditions, on the PK of AZD6793 after a single oral dose in healthy participants.
Time frame: Day 1 to Day 3
Part 3 (Food effect): AUCinf of AZD6793
Investigating the effect of a high fat high calorie (HFHC) meal compared to fasting conditions, on the PK of AZD6793 after a single oral dose in healthy participants.
Time frame: Day 1 to Day 3
Part 4 (COPD): Number of participants with adverse events
Safety and tolerability of AZD6793 following oral administration repeated up to 28 days (at least 26 days) in COPD participants.
Time frame: From screening up to Follow up visit (Day 34±2)
Part 4 (COPD): Number of participants with abnormal findings in vital signs (supine Blood Pressure (BP), pulse, respiratory rate, peripheral oxygen saturation (SpO2) and oral body temperature)
Safety and tolerability of AZD6793 following oral administration repeated up to 28 days (at least 26 days) in COPD participants.
Time frame: From screening up to Follow up visit (Day 34±2)
Part 4 (COPD): Number of participants with abnormal findings in 12 Lead electrocardiogram (ECG)
Safety and tolerability of AZD6793 following oral administration repeated up to 28 days (at least 26 days) in COPD participants.
Time frame: From screening up to Follow up visit (Day 34±2)
Part 4 (COPD): Number of participants with abnormal findings in Physical examinations
Safety and tolerability of AZD6793 following oral administration repeated up to 28 days (at least 26 days) in COPD participants.
Time frame: From screening, Treatment Day -1, 1, 14, 28 and follow up visit (34±2)
Part 4 (COPD): Number of participants with abnormal findings in Laboratory assessments (haematology, clinical chemistry, coagulation tests, and urinalysis)
Safety and tolerability of AZD6793 following oral administration repeated up to 28 days (at least 26 days) in COPD participants.
Time frame: From screening up to Follow up visit (Day 34±2)
Part 1 (SAD): Maximum observed plasma (peak) drug concentration (Cmax)
Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.
Time frame: Day 1 to Day 3
Part 1 (SAD): Time to reach peak or maximum observed concentration or response following drug administration (tmax)
Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.
Time frame: Day 1 to Day 3
Part 1 (SAD): Terminal rate constant, estimated by log linear least squares regression of the terminal part of the concentration time curve (λz)
Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.
Time frame: Day 1 to Day 3
Part 1 (SAD): Half life associated with terminal slope (λz) of a semi logarithmic concentration time curve ( t½λz)
Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.
Time frame: Day 1 to Day 3
Part 1 (SAD): Partial area under the plasma concentration time curve from time 0 to time 12 (AUC(0-12))
Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.
Time frame: Day 1 to Day 3
Part 1 (SAD): Partial area under the plasma concentration time curve from time 0 to time 24 (AUC(0-24))
Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.
Time frame: Day 1 to Day 3
Part 1 (SAD): Area under the plasma concentration curve from zero to the last quantifiable concentration (AUClast)
Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.
Time frame: Day 1 to Day 3
Part 1 (SAD): Area under plasma concentration time curve from zero to infinity (AUCinf)
Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.
Time frame: Day 1 to Day 3
Part 1 (SAD): Apparent total body clearance of drug from plasma after extravascular administration (CL/F)
Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.
Time frame: Day 1 to Day 3
Part 1 (SAD): Volume of distribution (apparent) at steady state following extravascular administration (based on terminal phase) (Vz/F)
Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.
Time frame: Day 1 to Day 3
Part 1 (SAD): Area under the plasma concentration time curve from time zero to time of last quantifiable analyte concentration divided by the dose administered (Dose normalised AUClast)
Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.
Time frame: Day 1 to Day 3
Part 1 (SAD): Area under the plasma concentration time curve from time zero extrapolated to infinity divided by the dose administered (Dose normalised AUCinf)
Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.
Time frame: Day 1 to Day 3
Part 1 (SAD): Maximum observed plasma (peak) drug concentration divided by the dose administered (Dose normalised Cmax).
Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.
Time frame: Day 1 to Day 3
Part 2 (MAD): Maximum observed plasma (peak) drug concentration (Cmax)
Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.
Time frame: Day 1 to Day 10
Part 2 (MAD): Concentration at the end of the dosing interval (Ctrough)
Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.
Time frame: Day 1 to Day 10
Part 2 (MAD): Temporal change parameter (TCP) assessed in urine
Characterizing pharmacokinetics of AZD6793 following oral administration of SAD in healthy participants.
Time frame: Day 1 and Day 8
Part 2 (MAD): Time to reach peak or maximum observed concentration or response following drug administration (tmax)
Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.
Time frame: Day 1 to Day 10
Part 2 (MAD): Terminal rate constant, estimated by log linear least squares regression of the terminal part of the concentration time curve (λz)
Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.
Time frame: Day 1 to Day 10
Part 2 (MAD): Half life associated with terminal slope (λz) of a semi logarithmic concentration time curve ( t½λz)
Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.
Time frame: Day 1 to Day 10
Part 2 (MAD): Partial area under the plasma concentration time curve from time 0 to time 24 (AUC(0-24))
Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.
Time frame: Day 1 to Day 10
Part 2 (MAD): Area under the plasma concentration curve from zero to the last quantifiable concentration (AUClast)
Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.
Time frame: Day 1 to Day 10
Part 2 (MAD): Area under plasma concentration time curve from zero to infinity (AUCinf)
Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.
Time frame: Day 1 to Day 10
Part 2 (MAD): Area under plasma concentration time curve in the dosing interval t (AUCt)
Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.
Time frame: Day 1 to Day 10
Part 2 (MAD): Apparent total body clearance of drug from plasma after extravascular administration (CL/F)
Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.
Time frame: Day 1 to Day 10
Part 2 (MAD): Volume of distribution (apparent) at steady state following extravascular administration (based on terminal phase) (Vz/F)
Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.
Time frame: Day 1 to Day 10
Part 2 (MAD): Area under the plasma concentration time curve from time zero to time of last quantifiable analyte concentration divided by the dose administered (Dose normalised AUClast)
Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.
Time frame: Day 1 to Day 10
Part 2 (MAD): Area under the plasma concentration-time curve from time zero to the dosing interval t concentration divided by the dose administered (Dose normalised AUCt)
Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.
Time frame: Day 1 to Day 10
Part 2 (MAD): Maximum observed plasma (peak) drug concentration divided by the dose administered (Dose normalised Cmax)
Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.
Time frame: Day 1 to Day 10
Part 2 (MAD): Ratio of the area under the curve (Rac AUC)
Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.
Time frame: Day 1 to Day 10
Part 2 (MAD): Accumulation ratio based on Cmax (Rac Cmax)
Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.
Time frame: Day 1 to Day 10
Part 2 (MAD): Cumulative amount of unchanged drug excreted into urine from time t1 to time t2 [Ae(t1 t2)]
Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.
Time frame: Day 1 and Day 8
Part 2 (MAD): Cumulative amount of unchanged drug excreted into urine (Aeinf)
Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.
Time frame: Day 1 and Day 8
Part 2 (MAD): Renal clearance of drug from plasma (CLR) assessed in urine
Characterizing pharmacokinetics of AZD6793 following oral administration of MAD in healthy participants.
Time frame: Day 1 and Day 8
Part 3 (Bioavailability): Cmax of AZD6793 (test Vs reference formulation)
To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants
Time frame: Day 1 to Day 3
Part 3 (Bioavailability): tmax of AZD6793 (test Vs reference formulation)
To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants
Time frame: Day 1 to Day 3
Part 3 (Bioavailability): λz of AZD6793 (test Vs reference formulation)
To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants
Time frame: Day 1 to Day 3
Part 3 (Bioavailability): t½λz of AZD6793 (test Vs reference formulation)
To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants
Time frame: Day 1 to Day 3
Part 3 (Bioavailability): AUC(0-12) of AZD6793 (test Vs reference formulation)
To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants
Time frame: Day 1 to Day 3
Part 3 (Bioavailability): AUC(0-24) of AZD6793 (test Vs reference formulation)
To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants
Time frame: Day 1 to Day 3
Part 3 (Bioavailability): AUClast of AZD6793 (test Vs reference formulation)
To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants
Time frame: Day 1 to Day 3
Part 3 (Bioavailability): AUCinf of AZD6793 (test Vs reference formulation)
To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants
Time frame: Day 1 to Day 3
Part 3 (Bioavailability): CL/F of AZD6793 (test Vs reference formulation)
To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants
Time frame: Day 1 to Day 3
Part 3 (Bioavailability): Vz/F of AZD6793 (test Vs reference formulation)
To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants
Time frame: Day 1 to Day 3
Part 3 (Bioavailability) :Relative bioavailability calculated as test AUC/reference AUC [Frel AUC]
To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants
Time frame: Day 1 to Day 3
Part 3 (Bioavailability): Relative bioavailability calculated as test Cmax/reference Cmax [Frel Cmax]
To assess the PK profiles of AZD6793 when administered as a test formulation versus reference formulation in healthy participants
Time frame: Day 1 to Day 3
Part 3 (Food effect): Cmax of AZD6793 (under fasted and fed state)
To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.
Time frame: Day 1 to Day 3
Part 3 (Food effect): tmax of AZD6793 (under fasted and fed state)
To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.
Time frame: Day 1 to Day 3
Part 3 (Food effect): λz of AZD6793 (under fasted and fed state)
To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.
Time frame: Day 1 to Day 3
Part 3 (Food effect): t½λz of AZD6793 (under fasted and fed state)
To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.
Time frame: Day 1 to Day 3
Part 3 (Food effect): AUC(0-12) of AZD6793 (under fasted and fed state)
To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.
Time frame: Day 1 to Day 3
Part 3 (Food effect): AUC(0-24) of AZD6793 (under fasted and fed state)
To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.
Time frame: Day 1 to Day 3
Part 3 (Food effect): AUClast of AZD6793 (under fasted and fed state)
To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.
Time frame: Day 1 to Day 3
Part 3 (Food effect): AUCinf of AZD6793 (under fasted and fed state)
To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.
Time frame: Day 1 to Day 3
Part 3 (Food effect): CL/F of AZD6793 (under fasted and fed state)
To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.
Time frame: Day 1 to Day 3
Part 3 (Food effect): Vz/F of AZD6793 (under fasted and fed state)
To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.
Time frame: Day 1 to Day 3
Part 3 (Food effect) :Frel AUC of AZD6793 (under fasted and fed state)
To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.
Time frame: Day 1 to Day 3
Part 3 (Food effect): Frel Cmax of AZD6793 (under fasted and fed state)
To examine the PK profiles of AZD6793 test formulation under fasted and fed (after intake of a HFHC meal) conditions in healthy participants.
Time frame: Day 1 to Day 3
Part 4 (COPD): Maximum observed plasma (peak) drug concentration (Cmax)
Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants
Time frame: Day 1 to Day 28
Part 4 (COPD): Concentration at the end of the dosing interval (Ctrough)
Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants
Time frame: Day 1 to Day 28
Part 4 (COPD): Temporal change parameter (TCP) assessed in urine
Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants
Time frame: Day 1 and Day 8
Part 4 (COPD): Time to reach peak or maximum observed concentration or response following drug administration (tmax)
Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants
Time frame: Day 1 to Day 28
Part 4 (COPD): Terminal rate constant, estimated by log linear least squares regression of the terminal part of the concentration time curve (λz)
Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants
Time frame: Day 1 to Day 28
Part 4 (COPD): Half life associated with terminal slope (λz) of a semi logarithmic concentration time curve ( t½λz)
Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants
Time frame: Day 1 to Day 28
Part 4 (COPD): Partial area under the plasma concentration time curve from time 0 to time 12 (AUC(0-12))
Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants
Time frame: Day 1 to Day 28
Part 4 (COPD): Partial area under the plasma concentration time curve from time 0 to time 24 (AUC(0-24))
Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants
Time frame: Day 1 to Day 28
Part 4 (COPD): Area under the plasma concentration curve from zero to the last quantifiable concentration (AUClast)
Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants
Time frame: Day 1 to Day 28
Part 4 (COPD): Area under plasma concentration time curve from zero to infinity (AUCinf)
Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants
Time frame: Day 1 to Day 28
Part 4 (COPD): Area under plasma concentration time curve in the dosing interval t (AUCt)
Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants
Time frame: Day 1 to Day 28
Part 4 (COPD): Apparent total body clearance of drug from plasma after extravascular administration (CL/F)
Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants
Time frame: Day 1 to Day 28
Part 4 (COPD): Volume of distribution (apparent) at steady state following extravascular administration (based on terminal phase) (Vz/F)
Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants
Time frame: Day 1 to Day 28
Part 4 (COPD): Ratio of the area under the curve (Rac AUC)
Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants
Time frame: Day 1 to Day 28
Part 4 (COPD): Accumulation ratio based on Cmax (Rac Cmax)
Characterizing the pharmacokinetic profile of AZD6793 following oral repeated administration up to 28 days (at least 26 days) in COPD participants
Time frame: Day 1 to Day 28
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Dec 2022 to primary completion in Oct 2024, 22 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AZD6793